Cover Image
市場調查報告書

Nanomerics Ltd- 產品平台檢討

Nanomerics Ltd - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 331740
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
Nanomerics Ltd- 產品平台檢討 Nanomerics Ltd - Product Pipeline Review - 2015
出版日期: 2015年04月29日 內容資訊: 英文 28 Pages
簡介

Nanomerics Ltd是總公司設在英國的奈米技術專門的製藥企業。該公司進行肽的片劑產品開發,產品系列有,治療慢性疼痛的內因性肽來源的口服止痛藥,及局部性眼科疾病的治療藥開發中疏水性高的醫藥品不利用刺激性界面活性劑和油脂的遞送解決方案,CyclosporineA的處方等。

本報告提供Nanomerics Ltd的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Nanomerics Ltd的基本資料

  • Nanomerics Ltd概要
  • 主要資訊
  • 企業資料

Nanomerics Ltd:R&D概要

  • 主要的治療範圍

Nanomerics Ltd:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Nanomerics Ltd:開發中產品概況

  • 在臨床階段的開發中產品
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Nanomerics Ltd:藥物簡介

  • amphotericin B nanoparticle
  • cyclosporine
  • NM-0127
  • Antibodies for Neurological Diseases
  • Drugs for Undisclosed Indication
  • NM-0132
  • NM-0134
  • NM-0141
  • NM-0151
  • NM-0161

Nanomerics Ltd:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Nanomerics Ltd:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

目錄
Product Code: GMDHC07020CDB

Summary

Global Markets Direct's, 'Nanomerics Ltd - Product Pipeline Review - 2015', provides an overview of the Nanomerics Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nanomerics Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Nanomerics Ltd including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Nanomerics Ltd's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Nanomerics Ltd's pipeline products

Reasons to buy

  • Evaluate Nanomerics Ltd's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Nanomerics Ltd in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Nanomerics Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Nanomerics Ltd and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nanomerics Ltd
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Nanomerics Ltd and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Nanomerics Ltd Snapshot
    • Nanomerics Ltd Overview
    • Key Information
    • Key Facts
  • Nanomerics Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Nanomerics Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Nanomerics Ltd - Pipeline Products Glance
    • Nanomerics Ltd - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Nanomerics Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Nanomerics Ltd - Drug Profiles
    • amphotericin B nanoparticle
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cyclosporine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NM-0127
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibodies for Neurological Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NM-0132
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NM-0134
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NM-0141
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NM-0151
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NM-0161
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Nanomerics Ltd - Pipeline Analysis
  • Nanomerics Ltd - Pipeline Products by Target
  • Nanomerics Ltd - Pipeline Products by Route of Administration
  • Nanomerics Ltd - Pipeline Products by Molecule Type
  • Nanomerics Ltd - Pipeline Products by Mechanism of Action
  • Nanomerics Ltd - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Nanomerics Ltd, Key Information
  • Nanomerics Ltd, Key Facts
  • Nanomerics Ltd - Pipeline by Indication, 2015
  • Nanomerics Ltd - Pipeline by Stage of Development, 2015
  • Nanomerics Ltd - Monotherapy Products in Pipeline, 2015
  • Nanomerics Ltd - Phase I, 2015
  • Nanomerics Ltd - Preclinical, 2015
  • Nanomerics Ltd - Pipeline by Target, 2015
  • Nanomerics Ltd - Pipeline by Route of Administration, 2015
  • Nanomerics Ltd - Pipeline by Molecule Type, 2015
  • Nanomerics Ltd - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Nanomerics Ltd - Pipeline by Top 10 Indication, 2015
  • Nanomerics Ltd - Pipeline by Stage of Development, 2015
  • Nanomerics Ltd - Monotherapy Products in Pipeline, 2015
  • Nanomerics Ltd - Pipeline by Top 10 Target, 2015
  • Nanomerics Ltd - Pipeline by Top 10 Molecule Type, 2015
  • Nanomerics Ltd - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top